Article
What Counts As Therapeutic Progress And Innovation In Longevity Biotechnology?
Longevity biotechnology is attracting increasing scientific, commercial, and investor interest. The unprecedented clinical success of GLP-1 on multiple age-associated conditions has prompted some to call it the first longevity drug, which has certainly boosted excitement for longevity biotechnology.
Foley & Lardner